TRANSCODE THERAPEUTICS, INC.
  • Home
  • About
    • Who We Are
    • Leadership
    • Partnering
  • Focus
  • Science
  • Pipeline
    • Platform
    • TTX-MC138
    • Other Candidates
  • Resources
  • Investors
  • Careers

Pipeline

THERAPEUTIC PIPELINE
We have created a platform of drug candidates with the objective of improving patient outcomes. Our lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has been shown to be responsible for approximately 90% of all cancer deaths annually. We believe that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. Additionally, the Company’s other drug candidates, TTX-siPDL1, TTX-siLIN28b, TTX-RIGA, TTX-CRISPR and TTX-mRNA, focus on treating cancer using RNA technology made possible through its proprietary delivery platform.
​Currently TransCode is continuing research on a variety of both diagnostic and therapeutic approaches targeting biomarkers broadly prevalent across numerous tumor types. 
Picture
* TransCode signed Exclusive Option Agreements with The General Hospital Corporation, d/b/a Massachusetts General Hospital, or MGH, for TTX-siLin28b and 64Cu-TTX-MC138. Under these Options, TransCode has the right to negotiate a license for these candidates with MGH.  TransCode’s decision will depend on the results of preclinical studies it plans to conduct as shown above.  
PDAC: Pancreatic ductal adenocarcinoma 
** Seeking Orphan designation status
***Received Orphan designation status from FDA
CLINICAL PLAN

Establishing Proof of Concept

As a next step, the company intends to advance TTX-MC138 to the clinic to be evaluated in human subjects suffering from late stage cancer. TransCode has received written guidance from the FDA in response to our pre-IND submission for our proposed first-in-human study​​ and we are proceeding ahead under that guidance. Based on the results of this study, the exploratory IND will be withdrawn, and a full IND will be submitted to support a Phase I/II clinical trial intended to evaluate safety and dose/response and treatment of patients with metastatic cancer.  ​


The FDA has not evaluated or approved TTX-MC138 and it is currently not available for patient use.
TTX is an investigational platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics which remain in development. Their safety and efficacy have not yet been evaluated by the FDA or any other regulatory agency.

Home

About

About
leadership

Partnering
​Careers     

Focus

Focus

Science

Science
​Resources

Pipeline

PIPELINE
TTX-MC138
​OTHER CANDIDATES

Contact/Support

Contact
​TERMS OF USE
PRIVACY POLICY
FCOI Policy
​
© TRANSCODE THERAPEUTICS, INC. 2022.​ ALL RIGHTS RESERVED.
  • Home
  • About
    • Who We Are
    • Leadership
    • Partnering
  • Focus
  • Science
  • Pipeline
    • Platform
    • TTX-MC138
    • Other Candidates
  • Resources
  • Investors
  • Careers